ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Camcevi (leuprolide mesylate) for the Treatment of Advanced Prostate Cancer
May 27, 2021Foresee announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Camcevi 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, as a treatment of advanced prostate cancer -
US approves AbbVie/Neurocrine’s uterine pain drug
July 26, 2018AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
Pharma Sources Insight January 2025
